The test’s ability to distinguish ALS from similar conditions is particularly noteworthy. It could help physicians differentiate between ALS and conditions that mimic its symptoms, such as primary ...
According to recent research, astrocyte cell transplantation could revolutionize treatments for neurological disorders such ...
CVN293 was generally well-tolerated in healthy volunteers for up to 14-days of continuous dosingDose-dependent exposure was ...
The past four years have brought disappointment for the Huntington’s community, but optimism is growing as companies ...
The Walk to Defeat ALS funds research, treatment, and a cure for Lou Gehrig’s Disease, otherwise known as ALS. The funds will ...
New research supports brain cell transplantation as a treatment for some neurological disorders. A team from McGill ...
Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for only two to five years after being diagnosed, according to the Centers for ...
FDA approves Autolus Therapeutics' Aucatzyl for adults with relapsed or refractory B-cell precursor acute lymphoblastic ...
Researchers have uncovered a mechanism that may trigger ALS’s earliest stages, identifying proteins that mislocalize, causing ...
Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for ...
On the heels of its most advanced medicine flunking a key study, the drugmaker is looking at the different paths it could ...
In September 2024, Athira announced topline results from the LIFT-AD Phase 2/3 clinical trial of fosgonimeton in mild-to-moderate Alzheimer’s disease. The study did not meet its primary or key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback